SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma

Summary

The purpose of the trial was to evaluate the efficacy and safety of SHR-1701 combined with fluzopar as a first-line treatment maintenance therapy for advanced lung squamous cell carcinoma. Patients with advanced or metastatic (stage IV) lung squamous cell carcinoma have not received systemic chemotherapy and have measurable lesions (RECIST 1.1) ECOG PS 0-1. The patient received SHR1701 +fluzoparib

Timeline

Start

2021-07-01

Primary completion

2024-12-01

Completion

2025-06-01

Drugs

Indications